Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040425 (tonsillitis)
 1,594 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

83 in-patients, age 3 months to 12 years, with tonsillitis, otitis, bronchitis and pneumonia were treated with a new galenic preparation of phenoxymethylpenicillin V potassium (Star-Pen Trockensirus SANABO). The drug was very well tolerated, no skin-rash was observed, no problems occurred with the oral administration. Diarrhea, not infrequent in oral penicillin therapy, was -- with one exception -- not noticed in patients above one year of age.
 ...
PMID:[Therapy of bacterial infections in infancy and childhood (author's transl)]. 11 4

The antibiotic management of tonsillitis, acute otitis media, sinusitis and bronchitis is critically reviewed. Tonsillitis due to Group A streptococci must be treated with penicillin for 10 days in order to prevent complications. Antibiotics should not be used locally in pharyngitis or tonsillitis. Tonsillectomy does neither reduce the incidence of streptococcal tonsillitis nor of rheumatic complications. Antibiotic cover for tonsillectomy is not indicated except in patients with rheumatic heart disease or in those with prosthetic heart valves. The indications for the prophylactic use of antibiotics in ear, nose and throat surgery are discussed.
 ...
PMID:[Antibiotic therapy - a critical review (author's transl)]. 45 63

The main purpose of the present study was to determine the qualitative and quantiative effect of various infectious epsiodes on the blood serum levels of retinol and retinol-binding protein (RBP). Twenty-four children and 30 adult subjects were studied. The infections studied included chickenpox (n = 7); bronchitis (n = 9) upper respiratory infection (n = 30); tonsillitis (n = 2); diarrhea (n = 2) and one case each of: febrile stomatitis, nonspecific gastrointestinal alteration, urinary infection and shigellosis. In addition to retinol and RBP, the study determined changes in serum carotene, proteins, albumin and globulins. The results clearly demonstrate the marked depressing effect of infections on serum retinol, with a magnitude which in many cases reached more than 20 micrograms/dl, and in others more than 30 micrograms/dl. The RBP levels were significantly correlated with retinol, decreasing proportionally with infection. Serum albumin also decreased in most instances; and the globulin levels of the children, but not of the adults, were significantly higher during the infections. Carotene did not show important variations. The effects were more intense when fever accompanied the infectious episodes. These results are considered of great public health significance, in view of the large majorities, mainly children, who ordinarily subsist with very low serum retinol levels in the underdeveloped regions of the world. As infections attack these underpriviledged children, their serum retinol and RBP levels will likely drop a magnitude similar to that observed in the subjects of this study. They may then reach even more critically deficient retinol levels and be in serious danger of developing a severe acute state of clinical vitamin A deficiency.
 ...
PMID:[Decrease in serum levels of retinol and its binding protein (RBP) in infection]. 57 85

380 athletes in optimal performance were examinated within 10 years between 2 and 13 times (average: 4 times): ECG were taken at rest, during breathing tests and under maximal physical load by ergometry. 88 (23.2%) of them showed arrhythmias, 32 in the same examination different forms of premature beats. All kinds of arrhythmias were seen except atrial flatter, total av-block and paroxysmal tachycardias. Breathing tests provoked most of arrhythmias followed by the recovery after maximal physical load. Follow-up studies and clinical examinations proved that in 86 sportsmen these arrhythmias were not a symptom of heart disease. Only in 2 athletes heart injury could not be excluded. But in nearly 50% extracardial inflammations, like tonsillitis, bronchitis etc., were found. It is discussed that bradycardia and vagotonia of the highly trained sportsmen cause the arrhythmias. This vagotonia is intensified by breathing tests. But arrhythmias found in athletes should cause an examination for other chronical sicknesses.
 ...
PMID:[Arrhythmias in athlets (author's transl)]. 70 72

We have undertaken some basic and clinical studies on midecamycin granules with following results: 1) After ingesting of 4 g of midecamycin granules, peak blood levels (1.51 microgram/ml on an average) appeared at one hour in infants, detectable amount lasting for 6 hours. 2) Urinary excretion within 6 hours ranged from 1.1 to 2.7% of the drug dosed. 3) In the treatment of a total of 19 acute cases, consisting of 9 cases of tonsillitis, 7 cases of lacunar tonsillitis and 3 cases of bronchitis, midecamycin was found effective in 79% of the cases. 4) In all the 3 cases of pneumonia due to Mycoplasma, response to midecamycin was assessed as excellent. 5) Hepatic and renal functions tests performed in cases treated with the drug for a prolonged period (40 approximately 50 mg/kg for 13 approximately 18 days) revealed no undesirable effect, indicating that midecamycin can be administered continuously to younger infants with infections.
 ...
PMID:[A study on midecamycin granules in acute respiratory diseases in infants (author's transl)]. 90 47

Clinical and laboratory studies on S-6437 were made, and the following results were obtained. 1. Thirty pediatric patients with various types of infections such as tonsillitis, bronchitis, pneumonia, cystitis, pyelitis, lymphadenitis colli and pyodermia were treated with S-6437 at the daily dosage of 50 mg/kg orally, the clinical effectiveness was 89.3%. 2. The peak blood level of cephalexin after a single oral administration (25 mg/kg) was observed after 4 hours and the average peak blood level of 10 cases was 7.4 microgram/ml. 3. The average urinary excretion rate of 5 cases was 71.2%. 4. Mild side effects were noticed in a few cases.
 ...
PMID:[Clinical and laboratory studies on S-6437 (a new longacting granule of cephalexin) in pediatric field (author's transl)]. 91 90

Forty-eight cases of otorhinolaryngological infections were treated with amoxicillin (AMPC) at a daily dose of 750mg. The clinical and microbiological effects were studied, and the results were summarized as follows. 1. The subjects comprised 20 cases of otitis media, 10 of tonsillitis, 4 of sinusitis, 4 of chroditis, 2 bronchitis, 5 of furuncle of the ear and 3 of furuncle of the nose. The clinical effective rate of AMPC was 82.9%, and the microbiological effective rate was 80.6%. 2. The effect of AMPC against strains isolated from the above diseases was also studied. The effective rate against Streptococcus was 91.6% and against Staphylococcus 83.3%. 3. Side effects were observed in 4 cases (one of diarrhea, two of abdominal discomfort and one of lingual pain), but none of them was so severe as the use of AMPC should have been discontinued.
 ...
PMID:[Clinical use of amoxicillin in the otorhinolaryngological field (authors's transl)]. 93 32

Cefprozil (CFPZ, BMY-28100) is a new oral cephem antibiotic without an ester linkage. Pharmacokinetic and clinical studies using CFPZ 10% fine granules were performed in pediatric patients. 1. Pharmacokinetic investigation Peak serum concentrations of CFPZ after dose of 7.5 mg/kg and 10 mg/kg were, respectively, 3.65 +/- 0.24 micrograms/ml and 6.38 +/- 3.23 micrograms/ml at 1-2 hours. The average half-life with 7.5 mg/kg administration was 0.90 +/- 0.16 hours and that with 10 mg/kg was 1.29 +/- 0.50 hours. The urinary excretion of CFPZ was about 45% (35.3-50.0%) in 6 hours. 2. Clinical investigation Enrolled in the study were 22 patients including 4 with pharyngitis, 3 with tonsillitis, 3 with bronchitis, 5 with pneumonia, 4 with urinary tract infection, and 1 each with pertussis, purulent lymphadenitis and otitis media. Responses were excellent in 14 patients, good in 5 patients and fair in 1 patient. In the assessment of the bacteriological efficacy, 8 out of 17 strains of organism identified previous to the treatment were eradicated, 5 strains were found replaced by other bacteria and 4 strains persisted, hence the eradication rate was 76.5%. 3. No adverse reactions attributable to the drug were observed. From the above results, it has been concluded that CFPZ is a highly effective and safe agent for moderate respiratory and urinary tract infections in children.
 ...
PMID:[Pharmacokinetic and clinical studies of cefprozil fine granules in children]. 128 90

These guidelines deal with the evaluation of anti-infective drugs for the treatment of respiratory tract infections. Five clinical entities are described: streptococcal pharyngitis and tonsillitis, otitis media, sinusitis, bronchitis, and pneumonia. A wide variety of microorganisms are potentially pathogenetic in these diseases; these guidelines focus on the bacterial infections. Inclusion of a patient in a trial of a new drug is based on the clinical entity, with the requirement that a reasonable attempt will be made to establish a specific microbial etiology. Microbiologic evaluation of efficacy requires isolation of the pathogen and testing for in vitro susceptibility. Alternatively, surrogate markers may be used to identify the etiologic agent. The efficacy of new drugs is evaluated with reference to anticipated response rates. Establishment of the microbial etiology of respiratory tract infections is hampered by the presence of "normal flora" of the nose, mouth, and pharynx, which may include asymptomatic carriage of potential pathogens. This issue is addressed for each category of infection described. For example, it is suggested that for initial phase 2 trials of acute otitis media and acute sinusitis tympanocentesis or direct sinus puncture be used to collect exudate for culture. Acute exacerbations of chronic bronchitis also present difficulties in the establishment of microbial etiology. These guidelines suggest that clinical trials employ an active control drug but leave open the possibility of a placebo-controlled trial. For pneumonia, the guidelines suggest the identification and enrollment of patients by the clinical type of pneumonia, e.g., atypical pneumonia or acute bacterial pneumonia, rather than by etiologic organism or according to whether it was community or hospital acquired. For each respiratory infection, the clinical response is judged as cure, failure, or indeterminate. Clinical improvement is not acceptable unless quantitative response measures can be applied.
 ...
PMID:Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. 147 53

Laboratory and clinical studies on cefprozil (CFPZ, BMY-28100), a new cephem antibiotic, were carried out in the field of pediatrics. The results obtained are summarized as follows: 1. Serum concentrations, urinary concentrations and urinary recovery rates of CFPZ were determined upon oral administration of CFPZ after meal at doses of 4 mg/kg granules in a case, 7.5 mg/kg granules in 2 cases and 15 mg/kg granules in one. Peak serum levels of CFPZ were obtained at an hour in 3 cases and at 2 hours in 1 case after administration of the drug with a range of 2.7-8.6 micrograms/ml with half-lives of 0.69-0.95 hours. Urinary recovery rates in the first 6 hours after administration ranged from 59.4-71.3%. 2. MICs of CFPZ against 36 clinical isolates (Staphylococcus aureus 4 strains, Streptococcus pneumoniae 5, Streptococcus pyogenes 5, Escherichia coli 5, Haemophilus influenzae 12, Haemophilus parainfluenzae 4, and Branhamella catarrhalis 1) were compared with those of cefaclor (CCL) and ampicillin (ABPC). The antibacterial activity of CFPZ was superior to those of CCL against Gram-positive cocci, and to those of ABPC against E. coli, and was equal to those of CCL and inferior to those of ABPC against H. influenzae. 3. Thirty-seven pediatric patients with acute infectious diseases (pharyngitis/tonsillitis 17, bronchitis 7, pneumonia 3, skin and soft tissue infection 2, and urinary tract infection 8) were treated with CFPZ at daily doses of 10-47 mg/kg t.i.d. as a rule. The efficacy rates were 100% clinically and 56% bacteriologically. 4. Side effects or abnormal laboratory test values were not observed except for an increased platelet count in 1 case and elevated GOT, GPT values in 2 cases.
 ...
PMID:[Laboratory and clinical studies on cefprozil in the field of pediatrics]. 149 37


1 2 3 4 5 6 7 8 9 10 Next >>